naproxen sodium

(redirected from Arranon)
Also found in: Thesaurus, Medical.
Related to Arranon: Arzerra, Clolar, Istodax
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.naproxen sodium - a nonsteroidal anti-inflammatory drug (trademarks Aleve and Anaprox and Aflaxen) that fights pain and inflammationnaproxen sodium - a nonsteroidal anti-inflammatory drug (trademarks Aleve and Anaprox and Aflaxen) that fights pain and inflammation
nonsteroidal anti-inflammatory, nonsteroidal anti-inflammatory drug, NSAID - an anti-inflammatory drug that does not contain steroids; "NSAIDs inhibit the activity of both Cox-1 and Cox-2 enzymes"
propanoic acid, propionic acid - a liquid fatty acid found in milk and sweat and in fuel distillates
References in periodicals archive ?
Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018.
The historic growth in major markets such as the US, the top five countries of Europe and Japan were driven mainly by the increasing prevalence and prescription population as well as launch of newer brands such as Sprycel, Tasigna, Clolar and Arranon with no major patent expirations.
If it does, Genmab will also have the option co-promote Bexxar and Arranon in the US and Atriance in the relevant countries of the Nordic region.
The drug, called Arranon, is being granted approval for use in both adults and children under a fast track scheme based on less clinical data than is normally required, but the company must continue its studies to prove that it prolongs survival.
The revenue of the leukemia treatment market has increased at a Compound Annual Growth Rate (CAGR) of 21% during the past eight years, due to the launch of new therapies including Sprycel (dasatinib), Tasigna (nilotinib), Clolar (cloferabine) and Arranon (nelarabine), which will continue to enjoy patent protection throughout the next six years covered by the report's forecast period.
There was a small piece of good news for GlaxoSmithkline as FDA briefing documents concluded that its cancer drug Arranon may offer benefits for treating rare kinds of blood cancer in some patients for whom chemotherapy has failed.
The moderate growth rate is primarily attributed to the patent expiry of Gleevec in 2015 in the US; 2016 in Europe, Clolar in 2015 in Europe and Arranon in 2017 in US; 2013 in Europe.
His work has contributed to the discovery or development of multiple oncology and antiviral medicines and drug candidates, including Zeffix, Emtriva, Ziagen, Arranon, and most recently ANA598 for HCV and ANA773 in oncology.